Effectiveness of Empagliflozin Added to Automated Insulin Delivery (AID) Systems in Adults With Type 1 Diabetes With Sub-optimal Glycemic Outcomes
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Empagliflozin, Placebo.
- Who it may be relevant to
- Registry conditions: Type 1 Diabetes. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Canada
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Effectiveness of Empagliflozin Added to Automated Insulin Delivery (AID) Systems in Adults With Type 1 Diabetes With Sub-optimal Glycemic Outcomes: a Randomized Controlled Parallel Trial
Overview
The goal of this 26-week multicenter, randomized, parallel, placebo-controlled trial is to test the effectiveness of empagliflozin use in conjunction with automated insulin delivery (AID) to improve glucose control in individuals with type 1 diabetes who do not meet target recommendations for time in range (3.9-10.0 mmol/L). The main question it aims to answer is: \- Will use of empagliflozin (2.5 mg/day) increase time spent in the target range of 3.9 to 10.0 mmol/L compared to placebo for individuals on an AID system who do not meet glycemic targets? Participants will either take 2.5 mg of empagliflozin or a placebo daily for 26 weeks while remaining on their current AID system.
Interventions
- Drug Empagliflozin
26-week use of automated insulin delivery system with empagliflozin (2.5 mg daily) in individuals with suboptimal time in range. - Drug Placebo
26-week use of automated insulin delivery system with placebo (daily) in individuals with suboptimal time in range.
Primary outcome measures
- Percentage of time of glucose levels spent in the target range (empagliflozin vs placebo) [Time frame: 4 weeks]
Secondary outcome measures (12)
- Percentage of time spent in the glucose range between 3.9 and 7.8 mmol/L [Time frame: 4 weeks]
- Percentage of time spent in the glucose range below 3.9 mmol/L and 3.0 mmol/L [Time frame: 4 weeks]
- Percentage of time spent in the glucose range above 10.0 mmol/L and 13.9 mmol/L [Time frame: 4 weeks]
- Mean glucose levels [Time frame: 4 weeks]
- Standard deviation of glucose levels [Time frame: 4 weeks]
- Coefficient of variance of glucose levels [Time frame: 4 weeks]
- Total insulin delivery (overall, basal, and bolus) [Time frame: 4 weeks]
- Mean daily carbohydrate intake [Time frame: 4 weeks]
- HbA1c [Time frame: 26 weeks]
- Estimated glomerular filtration rate (eGFR) [Time frame: 26 weeks]
- Lipid profile [Time frame: 26 weeks]
- Brain Natriuretic Peptide (NT-pro-BNP) [Time frame: 26 weeks]
Eligibility criteria
Inclusion criteria
- Individuals ≥ 18 years of age.
- A clinical diagnosis of type 1 diabetes for at least one year, as per the investigators' clinical judgment (confirmatory C-peptide and antibodies will not be required).
- Minimum 3-month use of a commercial advanced AID system.
- Time in range (3.9 to 10.0 mmol/L) < 70% on their personal AID system in the 30 days prior to screening (with minimum 70% time spent in closed-loop mode).
- Agreement to use a highly effective method of birth control for individuals of child-bearing age and active avoidance of pregnancy during the trial. Child-bearing potential refers to participants of the female sex post-menarche who have not reached menopause and who do not have a disclosed medical condition causing sterility (ex: hysterectomy). Post-menopausal state refers to the absence of menses for 12 months without any alternative cause.
Exclusion criteria
- Current or ≤ 2 week use of any anti-hyperglycemic agent other than insulin (such as SGTL2i).
- Current or ≤ 1 month use of Glucagon-like Peptide 1 (GLP1)-Receptor Agonists.
- Current or ≤ 1 month use of supraphysiological doses of oral or intravenous glucocorticoids.
- Planned or ongoing very low carbohydrate diet (< 50g/day).
- Glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2 as per CKD-EPI formula with creatinine levels measured within the last 12 months.
- Use of hydroxyurea.
- Planned or ongoing pregnancy.
- Breastfeeding.
- Ongoing active risk of recurrent genito-urinary infections, as per the clinical judgement of the investigators.
- Severe hypoglycemic episode within 1 month of screening, defined as an event resulting in seizure, loss of consciousness, or need to present to the emergency department.
- Diabetic ketoacidosis within 6 months of screening, defined as an event requiring the need to present to medical attention and administration of intravenous insulin.
- Any serious medical illness likely to interfere with the ability to complete the trial per the judgment of the investigators.
- Clinically significant retinopathy as judged by the investigator.
- Recent (< 3 months) acute macrovascular event (ex: acute coronary syndrome or cardiac surgery).
- Prior serious reaction to SGLT2i.
- Use of the Medtronic 670G or 770G system in the last 30 days.
- In the opinion of the investigator, inability to observe the contraindications of the study drugs, or failure to comply to the study protocol or research team's recommendations (e.g., changing pump parameters, ketone measurements).
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Quadruple blind
- Primary purpose
- Treatment
Study locations
Canada · 1 center
- McGill University Health Centre — Montreal
Identifiers
NCT: NCT06021145 · 2024-9953